DoxorubicinAntibiotics, AntineoplasticInduction ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsTaxoidsAntineoplastic AgentsCisplatinCombined Modality TherapyTreatment OutcomeRemission InductionCell Line, TumorDrug Resistance, NeoplasmPaclitaxelDrug Administration ScheduleChemotherapy, AdjuvantDisease-Free SurvivalBreast NeoplasmsCyclophosphamideSurvival AnalysisApoptosisCaspase 12Survival RateNeoplasm StagingFluorouracilLung NeoplasmsTumor Suppressor Protein p53EtoposideNeoadjuvant TherapyAntineoplastic Agents, PhytogenicVincristineDeoxycytidineCarboplatinHead and Neck NeoplasmsVinblastineCarcinoma, Squamous CellNeoplasm MetastasisCarcinoma, Non-Small-Cell LungInfusions, IntravenousNeutropeniaIfosfamideNeoplasm Recurrence, LocalDose-Response Relationship, DrugCytarabinePrognosisCardiomyopathiesDaunorubicinSalvage TherapyMaximum Tolerated DoseMitochondria, HeartAdenocarcinomaLeukemia, Myeloid, AcuteDNA DamageTumor Markers, BiologicalMethotrexateTime FactorsNeoplasmsLeukopeniaGene Expression Regulation, NeoplasticRNA, MessengerMyocardiumSignal TransductionKaplan-Meier EstimateRNA, Small InterferingHeartBleomycinRadiotherapy, AdjuvantFollow-Up StudiesAntimetabolites, AntineoplasticDisease ProgressionCamptothecinOrganoplatinum CompoundsMitoxantroneGranulocyte Colony-Stimulating FactorRadiotherapy DosageChemoradiotherapyRadiotherapyTumor BurdenBone NeoplasmsPrednisoneTransplantation, AutologousMelphalanEnzyme InductionAntibodies, MonoclonalEpirubicinAntibodies, Monoclonal, HumanizedBrain NeoplasmsAnthracyclinesPrecursor Cell Lymphoblastic Leukemia-LymphomaIdarubicinProspective StudiesLeucovorinOvarian NeoplasmsHypopharyngeal NeoplasmsThrombocytopeniaNasopharyngeal NeoplasmsBridged CompoundsTumor Necrosis Factor-alphaLiver NeoplasmsRetrospective StudiesRecurrence